Abiopharma

Cronos Brings Back Popular, Limited-Edition Spinach® Green Apple-Flavored Products for the Fall Season

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

Context Therapeutics to Participate in Upcoming Investor Conferences

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

NeoGenomics Reports Third Quarter 2025 Results

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Alkermes plc Reports Third Quarter 2025 Financial Results